CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 42 enrolled
Drug / intervention
Reveal LINQdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04169529
NCT04169529N/ACompleted
CompareCT.gov

Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)

Medtronic Cardiac Rhythm and Heart Failure·observational·Posted Nov 20, 2019·Updated Oct 26, 2024

In Brief

An observational study evaluating Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 42 participants across 9 sites.

Detailed Summary

The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 20, 2019
Enrollment StartAug 25, 2020
Primary CompletionJun 27, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.6 years ago

Interventions

Reveal LINQdevice

Insertion of Reveal LINQ device to characterize collected data from patients with COPD.